GLP-1 and SGLT2 Drugs Reduce Death in Heart Disease Patients, DPP-4 Inhibitors Do Not
A network meta-analysis of 129,465 patients showed GLP-1RAs reduce cardiovascular death by 13% and stroke by 13%, SGLT2i reduce heart failure hospitalization by 35%, while DPP-4 inhibitors have no cardiovascular benefit and may increase pancreatitis risk.
Quick Facts
What This Study Found
GLP-1RA: reduced CV death (OR 0.87), all-cause death (OR 0.88), stroke (OR 0.87) — all high-certainty. SGLT2i: reduced CV death (OR 0.82), all-cause death (OR 0.84), HF hospitalization (OR 0.65). DPP4i: no benefit on any CV outcome. DPP4i likely increase pancreatitis (OR 1.63). 129,465 participants, 20 studies.
Key Numbers
GLP-1RA CV mortality OR 0.87; SGLT2i CV mortality OR 0.82; SGLT2i HF hospitalization OR 0.65; DPP4i pancreatitis OR 1.63
How They Did This
Cochrane systematic review and network meta-analysis. 31 studies identified (287 records), 20 pooled (129,465 participants). 6 DPP4i, 7 GLP-1RA, 7 SGLT2i trials. Standard and network meta-analysis. GRADE certainty assessment. Risk of bias evaluation.
Why This Research Matters
This definitive comparison helps doctors choose the right diabetes drug for patients with heart disease. DPP-4 inhibitors clearly fall short, while GLP-1 and SGLT2 drugs save lives — with each class excelling at different cardiovascular endpoints.
The Bigger Picture
This meta-analysis reshapes the diabetes drug hierarchy. The clear cardiovascular superiority of GLP-1 and SGLT2 drugs over DPP-4 inhibitors supports guidelines recommending them as preferred second-line agents after metformin, especially in patients with established heart disease.
What This Study Doesn't Tell Us
No direct head-to-head comparisons between the three drug classes (network meta-analysis uses indirect comparisons). Most participants had established CVD — results may differ in primary prevention. Individual drug-level differences within classes not fully explored.
Questions This Raises
- ?Should DPP-4 inhibitors be deprioritized in guidelines given zero cardiovascular benefit?
- ?Do GLP-1 and SGLT2 drugs provide cardiovascular protection in non-diabetic heart disease patients?
- ?Would combining GLP-1RA + SGLT2i provide additive cardiovascular protection?
Trust & Context
- Key Stat:
- Zero CV benefit from DPP4i DPP-4 inhibitors showed OR 1.00 for cardiovascular death in high-certainty evidence — no benefit at all — while GLP-1 and SGLT2 drugs save lives
- Evidence Grade:
- High evidence: Cochrane systematic review and network meta-analysis with GRADE assessment. 129,465 participants across 20 RCTs. Most outcomes graded moderate-to-high certainty.
- Study Age:
- Published 2021. Additional cardiovascular outcome data has since reinforced the superiority of GLP-1RAs and SGLT2is over DPP4is.
- Original Title:
- Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
- Published In:
- The Cochrane database of systematic reviews, 10(10), CD013650 (2021)
- Authors:
- Kanie, Takayoshi, Mizuno, Atsushi, Takaoka, Yoshimitsu, Suzuki, Takahiro, Yoneoka, Daisuke, Nishikawa, Yuri, Tam, Wilson Wai San, Morze, Jakub, Rynkiewicz, Andrzej, Xin, Yiqiao, Wu, Olivia, Providencia, Rui, Kwong, Joey Sw
- Database ID:
- RPEP-05479
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Which diabetes drug class is best for heart protection?
This analysis of 129,465 patients shows GLP-1 drugs and SGLT2 inhibitors both reduce cardiovascular death and overall death. SGLT2i are best for preventing heart failure hospitalization. GLP-1 drugs are best for preventing stroke. DPP-4 inhibitors provide zero heart protection.
Should I switch from a DPP-4 inhibitor?
If you have established cardiovascular disease, this evidence strongly suggests GLP-1 drugs or SGLT2 inhibitors provide life-saving benefits that DPP-4 inhibitors lack. Talk to your endocrinologist about switching — especially if heart disease is a concern.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05479APA
Kanie, Takayoshi; Mizuno, Atsushi; Takaoka, Yoshimitsu; Suzuki, Takahiro; Yoneoka, Daisuke; Nishikawa, Yuri; Tam, Wilson Wai San; Morze, Jakub; Rynkiewicz, Andrzej; Xin, Yiqiao; Wu, Olivia; Providencia, Rui; Kwong, Joey Sw. (2021). Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.. The Cochrane database of systematic reviews, 10(10), CD013650. https://doi.org/10.1002/14651858.CD013650.pub2
MLA
Kanie, Takayoshi, et al. "Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.." The Cochrane database of systematic reviews, 2021. https://doi.org/10.1002/14651858.CD013650.pub2
RethinkPeptides
RethinkPeptides Research Database. "Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 r..." RPEP-05479. Retrieved from https://rethinkpeptides.com/research/kanie-2021-dipeptidyl-peptidase4-inhibitors-glucagonlike
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.